EXEL vs. IQV: Exelixis vs. IQVIA Stock Comparison

November 11, 2026

How do Exelixis (EXEL) and IQVIA (IQV) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Exelixis (EXEL) and IQVIA (IQV) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but EXEL is classified in Biotechnology while IQV is classified in Life Sciences Tools & Services.

Company profile comparison for Exelixis (EXEL) and IQVIA (IQV)
Profile Item	EXEL	IQV
Name	Exelixis Inc.	IQVIA Holdings Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	16.98 billion USD	44.80 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	April 17, 2000	May 9, 2013
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

EXEL

IQV

GSPC

Exelixis (EXEL) vs. IQVIA (IQV), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Exelixis (EXEL) and IQVIA (IQV). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Exelixis (EXEL) and IQVIA (IQV). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Exelixis (EXEL) and IQVIA (IQV)
Metric	EXEL	IQV
Total Return (1Y)	74.98%	32.11%
Total Return (3Y, Annualized)	50.33%	13.15%
Total Return (5Y, Annualized)	31.10%	2.00%

Risk Profile

Drawdown History

EXEL

IQV

GSPC

Exelixis (EXEL) vs. IQVIA (IQV), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Exelixis (EXEL) and IQVIA (IQV). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Exelixis (EXEL) and IQVIA (IQV)
Metric	EXEL	IQV
Volatility (1Y, Annualized)	34.17%	40.77%
Beta (5Y)	0.41	1.14
Max Drawdown (5Y)	-35.41%	-51.52%
Avg. Volume (3M)	2.33M	1.40M

Risk-Adjusted Performance

Risk-Return Positioning

EXEL and IQV are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Exelixis (EXEL) and IQVIA (IQV)
Metric	EXEL	IQV
Sharpe Ratio (1Y)	2.07	0.68
Sortino Ratio (1Y)	3.23	1.03

Profitability

ROE (TTM)

Both Exelixis (EXEL) at 44.32% and IQVIA (IQV) at 21.39% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.32%

Max: 109.18%
EXEL: 44.32%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.39%

Max: 109.18%
IQV: 21.39%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Exelixis (EXEL) vs. IQVIA (IQV): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Exelixis (EXEL) at 35.45% keeps the most of each sales dollar — above its industry’s net margin range — and IQVIA (IQV) at 8.05% also retains a top-quartile share.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.45%

EXEL: 35.45%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.05%

Max: 18.05%
IQV: 8.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Exelixis (EXEL) vs. IQVIA (IQV): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Exelixis (EXEL) at 40.75% operates in the top operating margin quartile, ahead of IQVIA (IQV) at 13.73%, which runs around its industry’s norm.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.75%

Max: 83.12%
EXEL: 40.75%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.73%

Max: 83.12%
Q3: 14.77%
IQV: 13.73%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Exelixis (EXEL) vs. IQVIA (IQV): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Exelixis (EXEL) and IQVIA (IQV)
Metric	EXEL	IQV
ROE (TTM)	44.32%	21.39%
ROA (TTM)	23.52%	5.08%
Net Margin (TTM)	35.45%	8.05%
Operating Margin (TTM)	40.75%	13.73%
Gross Margin (TTM)	96.26%	33.07%

Growth

Revenue Growth

Both Exelixis (EXEL) at 6.98% and IQVIA (IQV) at 5.87% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Exelixis (EXEL) vs. IQVIA (IQV): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Exelixis (EXEL) at 57.95% and IQVIA (IQV) at 4.67% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Exelixis (EXEL) vs. IQVIA (IQV): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Exelixis (EXEL) and IQVIA (IQV)
Metric	EXEL	IQV
Revenue Growth (YoY)	6.98%	5.87%
Revenue Growth (3Y CAGR)	12.93%	4.21%
EPS Growth (YoY)	57.95%	4.67%
EPS Growth (3Y CAGR)	70.59%	11.08%

Financial Strength

Current Ratio (MRQ)

Exelixis (EXEL) at 3.21 keeps current ratio within its industry’s typical mid-range, while IQVIA (IQV) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for IQV.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.21

Max: 25.13
Q3: 12.13
Median: 5.52
EXEL: 3.21
Q1: 2.47
Min: 0.10

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
IQV: 0.83
Min: 0.10

Exelixis (EXEL) vs. IQVIA (IQV): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Exelixis (EXEL) at 0.09 is near its industry mid-range for debt-to-equity ratio, while IQVIA (IQV) at 2.40 sits above its benchmark range, pointing to a heavier debt load relative to equity.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max: 1.42
Q3: 0.65
Median: 0.15
EXEL: 0.09
Q1: 0.02
Min: 0.00

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40

IQV: 2.40
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Exelixis (EXEL) vs. IQVIA (IQV): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Exelixis (EXEL) and IQVIA (IQV)
Metric	EXEL	IQV
Current Ratio (MRQ)	3.21	0.83
Debt / Equity (MRQ)	0.09	2.40
Net Debt / EBITDA	-0.71	4.46

Dividends

Dividend Yield (TTM)

Neither Exelixis (EXEL) nor IQVIA (IQV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

IQV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Exelixis (EXEL) vs. IQVIA (IQV): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Exelixis (EXEL) nor IQVIA (IQV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

IQV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Exelixis (EXEL) vs. IQVIA (IQV): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Exelixis (EXEL) and IQVIA (IQV)
Metric	EXEL	IQV
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Both Exelixis (EXEL) at 20.83 and IQVIA (IQV) at 33.07 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.83

Max: 85.34
Q3: 43.46
Median: 26.69
EXEL: 20.83
Q1: 13.30
Min: 0.07

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.07

Max: 85.34
Q3: 43.46
IQV: 33.07
Median: 26.69
Q1: 13.30
Min: 0.07

Exelixis (EXEL) vs. IQVIA (IQV): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

IQVIA (IQV) at 2.59 sits in the cheaper P/S ratio quartile while Exelixis (EXEL) at 6.80 prices around its industry’s middle — IQV costs less per dollar of sales, though read it alongside growth and margins.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.80

Max: 58.18
Q3: 25.77
Median: 7.30
EXEL: 6.80
Q1: 3.01
Min: 0.01

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.59

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
IQV: 2.59
Min: 0.01

Exelixis (EXEL) vs. IQVIA (IQV): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both Exelixis (EXEL) at 9.28 and IQVIA (IQV) at 6.73 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.28

Max: 13.53
EXEL: 9.28
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.73

Max: 13.53
IQV: 6.73
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Exelixis (EXEL) vs. IQVIA (IQV): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Exelixis (EXEL) and IQVIA (IQV)
Metric	EXEL	IQV
P/E Ratio (TTM)	20.83	33.07
P/S Ratio (TTM)	6.80	2.59
P/B Ratio (MRQ)	9.28	6.73
Free Cash Flow Yield (TTM)	4.47%	4.72%